Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509257 | 1.00 | LCK (0.50) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL28230152 | 0.98 | LCK (0.49) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL3468306 | 0.98 | LCK (0.49) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL29486326 | 0.98 | LCK (0.49) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL17237902 | 0.96 | LCK (0.47) | LCKKDRJAK3MAPK14PDPK1 | |
| Piperazine SCHEMBL4796334 | 0.88 | LCK (0.43) | LCKKDRJAK3MAPK14PDPK1 | |
| Biphenyl SCHEMBL28889831 | 0.85 | ADORA2A (0.51) | LCKKDRJAK3MAPK14EGFR | |
| SCHEMBL29109657 | 0.84 | METAP2 (0.46) | LCKKDRJAK3MAPK14PDPK1 | |
| Trifluoroacetic Acid SCHEMBL28209915 | 0.82 | ADORA3 (0.40) | LCKKDRJAK3MAPK14DCPS | |
| SCHEMBL28018342 | 0.81 | GRM4 (0.51) | LCKKDRJAK3MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | claimed |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | claimed |
| EP-4648800-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4648801-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | claimed |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-10 | — | — | US | claimed |
| CN-119746092-A | Preparation method of bio-based nano-drug capable of controlling slow release through reversible covalent bonds | 南京林业大学 | 2025-04-04 | — | — | CN | claimed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | claimed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | claimed |
| EP-1196419-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2002-04-17 | — | — | EP | claimed |
| US-20020032262-A1 | 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds | ZHANG JINFANG (US) | 2002-03-14 | — | — | US | claimed |
| US-20010055570-A1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives | NAEF RETO (CH) | 2001-12-27 | — | — | US | claimed |
| EP-1140044-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | Novartis AG (CH) | 2001-10-10 | — | — | EP | claimed |
| WO-2001034574-A1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2001002406-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-01-11 | — | — | WO | claimed |
| WO-2000037061-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | claimed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | LCK 1211/4885KDR 2554/4885JAK3 506/4885 |
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | LCK 4660/4885KDR 4504/4885JAK3 4135/4885 |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | LCK 3883/4885KDR 480/4885JAK3 3956/4885 |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | PTK2B, PTK2, LTK | LCK 17/4885KDR 2036/4885JAK3 772/4885 |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | MGAT3, GALE, GPI | LCK 3638/4885KDR 1343/4885JAK3 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.